TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8128082

Group type: EXPERIMENTAL
Intervention: Combined antegrade‐retrograde cardioplegia with perfusion into the right atrium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cardioplegia through the aortic root
Number of subjects: 40
Study: 2577483

Group type: EXPERIMENTAL
Intervention: Coated 5-ASA (Claversal) 0.75 g/day
Number of subjects: 334

Group type: COMPARATOR
Intervention: Sulphasalazine 1.5-2.0 g/day
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Coated 5-ASA
Number of subjects: 334

Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 334
Study: 329621

Group type: EXPERIMENTAL
Intervention: Trichloroethylene (TCE) exposure
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 7
Study: 31910674

Group type: EXPERIMENTAL
Intervention: Video-feedback interaction guidance intervention (3 sessions during home visits at 3-week intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (3 home visits on the same schedule as intervention)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Video-feedback interaction guidance intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 29769505

Group type: EXPERIMENTAL
Intervention: 20mg 0.5% hyperbaric bupivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 15mg 0.5% hyperbaric bupivacaine plus 5mg dexamethasone
Number of subjects: 72
Study: 27383931

Group type: EXPERIMENTAL
Intervention: Robotic lobectomy
Number of subjects: 10
Study: 23524886

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Both belimumab doses
Number of subjects: 1684
Study: 23298524

Group type: EXPERIMENTAL
Intervention: Supplemental omega-3 fatty acids (3.18 g daily of eicosapentaenoic acid and 822 mg daily of docosahexaenoic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control soy oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemental omega-3 fatty acids
Number of subjects: 0
Study: 20859868

Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg daily for 1 month
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18445899

Group type: EXPERIMENTAL
Intervention: ESWL + 40 mg of furosemide
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard ESWL
Number of subjects: 87
Study: 15986358

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention
Number of subjects: 142
Study: 12558462

Group type: EXPERIMENTAL
Intervention: Losartan 50 or 100 mg/day
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 10338106

Group type: EXPERIMENTAL
Intervention: 12 g piracetam daily for 4 weeks and maintenance treatment for 8 weeks
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: 12 g piracetam
Number of subjects: 927
Study: 7860900

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Combination of APSAC and rt-PA
Number of subjects: 278
Study: 1781340

Group type: EXPERIMENTAL
Intervention: Phenobarbital (administered prenatally in a small dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital (in utero exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to xenobiotics
Number of subjects: 0
Study: 7282057

Group type: EXPERIMENTAL
Intervention: Oral loperamide, doses of 2-6 mg per day
Number of subjects: 7
Study: 31148398

Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production (EHFP)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production plus fishponds (EHFP + F)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 900
Study: 28228428

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure treatment (target <120/80 mm Hg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard blood pressure treatment (target <140/90 mm Hg)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure treatment
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 184
Study: 25795641

Group type: EXPERIMENTAL
Intervention: Automated Bolus Advisors (BAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24096552

Group type: EXPERIMENTAL
Intervention: Copper supplementation (8 mg/day as copper sulfate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22093394

Group type: EXPERIMENTAL
Intervention: Crowe Critical Appraisal Tool (CCAT group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Informal appraisal (IA group)
Number of subjects: 10
Study: 19477399

Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring using OptiVol in Medtronic implantable devices
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nominal 'alarm' threshold value for identification of episodes of decompensation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Fluid Trend data after a true positive alarm
Number of subjects: 500
Study: 18180892

Group type: EXPERIMENTAL
Intervention: Tiaozhi Yanggan Decoction (TZYGD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Thiola (Control)
Number of subjects: 101
Study: 15345918

Group type: EXPERIMENTAL
Intervention: Classic heparin with Hemophan membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with Hemophan membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Classic heparin with ethylene vinyl alcohol membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with ethylene vinyl alcohol membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Classic heparin with polyacrylonitrile membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with polyacrylonitrile membrane
Number of subjects: 10
Study: 10858407

Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 32
Study: 9105569

Group type: EXPERIMENTAL
Intervention: L-arginine (7 g three times per day for 3 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8255447

Group type: EXPERIMENTAL
Intervention: Vigabatrin (3 grams oral daily add-on therapy)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (daily add-on therapy)
Number of subjects: 168
Study: 3516908

Group type: EXPERIMENTAL
Intervention: Dermodress
Number of subjects: 10

Group type: COMPARATOR
Intervention: Furacin gauze
Number of subjects: 10
Study: 31659608

Group type: EXPERIMENTAL
Intervention: SAFEChildren preventive intervention applied during first grade
Number of subjects: 424

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 424
Study: 28745475

Group type: EXPERIMENTAL
Intervention: BodyPump (high‐repetition, low to moderate load RT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Heavy load RT (linear periodization with 3‐6, 8‐10 and 13‐15 repetitions, 2‐4 series)
Number of subjects: 18
Study: 27100716

Group type: EXPERIMENTAL
Intervention: Non-anesthesiologist administration of propofol (Group A)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Anesthesiologist-administered sedation (Group B)
Number of subjects: 277
Study: 24177711

Group type: EXPERIMENTAL
Intervention: Halliwick‐Therapy (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 30
Study: 22244014

Group type: EXPERIMENTAL
Intervention: Orafti® Synergy1 (β2-1 fructans) 8 g/d
Number of subjects: 43

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 43
Study: 20924148

Group type: EXPERIMENTAL
Intervention: High‐number long‐interval (HL) arm flex/extend exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low‐number short‐interval (LS) arm flex/extend exercise
Number of subjects: 8
Study: 18980521

Group type: EXPERIMENTAL
Intervention: SRP plus 0.5% AZM (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SRP only (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 16204748

Group type: EXPERIMENTAL
Intervention: Abciximab with an initial heparin bolus of 50 U/kg (n = 128)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo with an initial heparin bolus of 70 U/kg (n = 126)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Abciximab group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 254
Study: 12414410

Group type: EXPERIMENTAL
Intervention: Low-concentration homogenized castor oil eye drops (2% castor oil and 5% polyoxyethylene castor oil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 20
Study: 9498724

Group type: EXPERIMENTAL
Intervention: Ketamine (i.v. bolus of 0.26 mg/kg followed by an infusion of 0.65 mg/kg per hour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg, PO
Number of subjects: 23
Study: 7883925

Group type: EXPERIMENTAL
Intervention: Pontoon spica group (treated with a few days in traction followed by 90‐90 pins‐in‐plastic spica)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Traditional group (treated with 3 weeks in traction followed by spica)
Number of subjects: 91
Study: 2294135

Group type: EXPERIMENTAL
Intervention: Increased dietary calcium intake (dairy products) by an average of 610 mg/day for 3 years
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (age- and weight-matched women)
Number of subjects: 37
Study: 118329

Group type: EXPERIMENTAL
Intervention: Continuation of chemotherapy for an additional three years
Number of subjects: 220

Group type: COMPARATOR
Intervention: Discontinuation of therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Total patient group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Males in randomized group
Number of subjects: 220
Study: 30496350

Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 100 mg tribendimidine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 29079039

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoate 2g/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vitamins E 364mg/day + C 1000mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of ethyl-EPA and vitamins E+C
Number of subjects: 53
Study: 26854288

Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intra-abdominal removal of the placenta
Number of subjects: 210
Study: 24991933

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT) at 3 L/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acetazolamide (2 × 250 mg tablets)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: All treatments (NOT, acetazolamide, placebo)
Number of subjects: 23
Study: 23173988

Group type: EXPERIMENTAL
Intervention: Birth seat group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (any other position for vaginal birth)
Number of subjects: 0
Study: 21058210

Group type: EXPERIMENTAL
Intervention: 8-week resistance training programme
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 17362708

Group type: EXPERIMENTAL
Intervention: Condom counseling provided during the screening visit
Number of subjects: 314

Group type: COMPARATOR
Intervention: Prior to counseling
Number of subjects: 314
Study: 15602643

Group type: EXPERIMENTAL
Intervention: Ash Split catheter (AS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: PermCath catheter (PC)
Number of subjects: 69
Study: 12540325

Group type: EXPERIMENTAL
Intervention: Nurse-initiated chart review and prompt to physicians
Number of subjects: 997

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 997
Study: 9822508

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 8.4% sodium bicarbonate (1:10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine lumbar epidural anesthesia
Number of subjects: 24
Study: 8132440

Group type: EXPERIMENTAL
Intervention: mianserine (30-60 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: fluvoxamine (50-100 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 2679331

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.75 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 1.5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 2.5 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (0 mg diamorphine)
Number of subjects: 35
Study: 1177541

Group type: EXPERIMENTAL
Intervention: CPR training by usual teachers who received special educational program
Number of subjects: 100
Study: 535777

Group type: EXPERIMENTAL
Intervention: Lisuride 600 micrograms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lisuride 900 micrograms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lisuride 100 micrograms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lisuride 200 micrograms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lisuride 300 micrograms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bromocryptine 2.5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31008634

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 592

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 592
Study: 30134883

Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham tape (ST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 39
Study: 26777100

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 380
Study: 27128840

Group type: EXPERIMENTAL
Intervention: Siltuximab derived from Sp2/0 cell line
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Siltuximab derived from CHO cell line
Number of subjects: 0
Study: 22434736

Group type: EXPERIMENTAL
Intervention: Monthly newsletters
Number of subjects: 53

Group type: COMPARATOR
Intervention: Monthly group classes and telephone behavioural sessions
Number of subjects: 53
Study: 19067471

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Uptitration of olmesartan medoxomil/amlodipine to 20/5 mg, 40/5 mg, or 40/10 mg
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo plus amlodipine 5 mg for 8 weeks
Number of subjects: 755
Study: 15288987

Group type: EXPERIMENTAL
Intervention: Glasses with or without patches
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Glasses alone
Number of subjects: 177

Group type: COMPARATOR
Intervention: Deferred treatment for 1 year
Number of subjects: 177
Study: 12213846

Group type: EXPERIMENTAL
Intervention: HYPO (hypothyroid)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: HYPO + rhTSH (hypothyroid + recombinant human TSH)
Number of subjects: 162
Study: 9620508

Group type: EXPERIMENTAL
Intervention: Midazolam (Mz) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol (Pf) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam (Mz) in combination with Propofol (Pf)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study: 7650148

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 2655365

Group type: EXPERIMENTAL
Intervention: 0.5% mepivacaine with epinephrine 5 micrograms/ml (3 ml at each pin site)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study: 814825

Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no hyperalimentation)
Number of subjects: 34
Study: 31797548

Group type: EXPERIMENTAL
Intervention: Customized healing abutment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard healing abutment
Number of subjects: 36
Study: 30477858

Group type: EXPERIMENTAL
Intervention: Water-soluble cinnamon extract
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 27579926

Group type: EXPERIMENTAL
Intervention: Telephone intervention (6 interventions over 6 months)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional monitoring (control group)
Number of subjects: 210
Study: 24474147

Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22699287

Group type: EXPERIMENTAL
Intervention: gevokizumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study: 20575921

Group type: EXPERIMENTAL
Intervention: Open staff-assisted glove donning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Closed staff-assisted glove donning
Number of subjects: 40
Study: 18487887

Group type: EXPERIMENTAL
Intervention: Traditional Taiji and Qigong (TQ) practice for 5 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Traditional Taiji and Qigong (TQ) practice
Number of subjects: 50
Study: 15853863

Group type: EXPERIMENTAL
Intervention: bupropion SR (days 1-3, 150 mg/day; days 4-49, 150 mg twice daily)
Number of subjects: 690

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 690
Study: 12861232

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min/day, 5 days/week) for 16 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 131
Study: 11292113

Group type: EXPERIMENTAL
Intervention: Inhaled Ems salt
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inhaled isotonic saline
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaled Ems salt (cough group)
Number of subjects: 43
Study: 8619450

Group type: EXPERIMENTAL
Intervention: Two 400-mg doses of artesunate followed by two doses of mefloquine (750 mg immediately and 500 mg 12 hr later)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Four 200-mg doses of artesunate given 12 hr apart followed by a mefloquine regimen similar to Group I
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Group II (four 200-mg doses of artesunate followed by mefloquine)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Group I (two 400-mg doses of artesunate followed by mefloquine)
Number of subjects: 111
Study: 1313591

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study: 3891239

Group type: EXPERIMENTAL
Intervention: Amcinonide ointment applied twice daily for two weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment applied twice daily for two weeks
Number of subjects: 34
Study: 30031995

Group type: EXPERIMENTAL
Intervention: Activity based group therapy (1 hour duration, once a week for 4 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Activity based group therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (assessed using the State‐Trait Anxiety Inventory (STAI‐S) once at recruitment and again 4 weeks later)
Number of subjects: 34
Study: 27419804

Group type: EXPERIMENTAL
Intervention: Low fluence, high repetition rate 810-nm diode laser in SHR mode
Number of subjects: 92

Group type: COMPARATOR
Intervention: High fluence, low repetition rate diode laser in HR mode
Number of subjects: 92
Study: 23390066

Group type: EXPERIMENTAL
Intervention: 12-session reality therapy drug treatment program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 22743149

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 16 weeks
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 288
Study: 20483194

Group type: EXPERIMENTAL
Intervention: Topical anesthesia using liposomal lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vapocoolant spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-administered tactile stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed distraction (reading a magazine)
Number of subjects: 0
Study: 18304971

Group type: EXPERIMENTAL
Intervention: Interactive, learner‐centred educational methods in large and small group settings
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard programme of continuing medical education (CME)
Number of subjects: 192
Study: 16115125

Group type: EXPERIMENTAL
Intervention: MMSET transfected cell lines
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: t(4;14)+ MM patients
Number of subjects: 37
Study: 12433720

Group type: EXPERIMENTAL
Intervention: IGF-I levels in cases
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: IGFBP-3 levels in cases
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: IGF-I levels in heaviest smokers (2nd to 4th quartiles)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: IGFBP-3 levels in highest quartile
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: IGF-I levels in younger subjects
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Current smoking or recent cessation effects on IGF-I levels
Number of subjects: 456